Calypte Biomed, hab heute wieder mal gekauft !

schaut der Chart von Caly besch...eiden aus. Achne, ist ja nur eine kurze Schwächephase...*g*

So long,
Calexa
www.investorweb.de

                  approved for testing blood serum,
                  plasma or whole blood to detect
                  antibodies to the virus that causes
                  AIDS. Trinity said the trial data it
                  submitted to the FDA showed that its
                  test detected 100% of the HIV
                  positive specimens and was 99.7%
                  accurate on the negative samples for
                  about 9,000 patients. OraSure's
                  OraQuick Rapid HIV-1 test, approved
                  in November 2002, takes 20 minutes
                  but can only be used on whole blood.
                  Both tests are a step up from
                  conventional laboratory tests, which
                  often take hours or days to give a
                  result.

                  Trinity, which plans to market the test
                  to government programs and
                  physicians, expects hospitals to be its
                  main market. The company says the
                  test could provide immediate help to
                  medical professionals who are stuck
                  with potentially contaminated needles
                  about 800,000 times a year and
                  require an immediate HIV test. In
                  addition, about 200,000 pregnant
                  women at risk for HIV are tested in
                  hospitals each year.

                  Currently, Trinity's test is sold in Africa
                  and Asia and approved for the World
                  Health Organization's HIV testing
                  program in Africa. The company sells
                  about four million tests in Africa and
                  expects to sell between 400,000 and
                  500,000 tests in the U.S. next year.
                  Trinity says the conversion of
                  lab-based HIV tests to rapid tests
                  represents an annual market
                  opportunity of $30 million.

                  For the third quarter, the company,
                  which makes more than 500
                  diagnostic products for detecting a
                  variety of diseases and disorders,
                  posted a profit of $1.8 million, or four
                  cents a share, on revenue of $16.9
                  million.

                  Rodman & Renshaw's Piros predicts
                  Trinity will earn 14 cents a share for
                  2003. Next year, he projects the HIV test will bring in sales of $5 million, rising to $8
                  million in 2005 and $11.5 million in 2006. While that $11.5 million would only be 13% of
                  total revenue, Piros predicts it will be 20% of gross margins, bringing annual profits to
                  23 cents a share.

                  Prior to Monday's announcement, the consensus estimate among analysts polled by
                  Thomson First Call was for Trinity to earn 17 cents a share for 2003 and 19 cents for
                  2004.

                  "Trinity's revenue growth rate has been about 25% per annum; we've been a very
                  acquisitive company," says Trinity President Brendan Farrell. "Earnings growth has not
                  matched as fast, since we have invested a lot in a direct sales force in Germany and the
                  U.S. But earnings should match revenue growth going forward."

                  Farrell says the HIV test currently accounts for 7% of the 12-year-old company's
                  revenue, which he estimates to be about $67 million this year. Gross margins are
                  currently 45%. He expects the test to sell for between $10 and $13, and bring in gross
                  margins "north of 80%." By the end of 2004, 15% of the company's sales will come from
                  the HIV test, with about half from the U.S.

                  According to Piros, the wildcard in the equation is the adoption by physicians outside of
                  hospitals, which he hasn't included in his calculations. That's because family doctors
                  may avoid the rapid HIV test since they'd need to offer immediate counseling to those
                  testing positive.

                  But problems over at OraSure may give Trinity an opportunity to corner more of the
                  market quickly. Even though OraSure's test has been available for a year, three months
                  ago the company terminated its marketing relationship with Abbott Laboratories
                  (ABT), its sole distributor. OraSure cited Abbott's failure to meet its obligation of
                  minimum monthly purchases.

                  "Orasure had a 12-month lead," says Piros, "but it was equalized by the fact Abbott
                  didn't carry the day. Now, it needs to do the same process as Trinity does with building
                  a sales force. Plus, the OraSure version test isn't as user friendly in the hospital
                  environment as the Trinity product."

                  Quote:
                  "The playing field is level right now," says Rodman & Renshaw's Piros, "the only
                  difference being Trinity has a better quality test. OraSure is currently valued at $340
                  million and Trinity is valued at half that much. The key difference is perception because
                  OraSure was the market leader. But according to our thesis, this difference could be cut
                  and the situation could completely reverse during the next six to 12 moths after Trinity
                  establishes that its test is more favorable and will be adopted." (Piros doesn't own
                  shares of Trinity Biotech; Rodman & Renshaw has an investment-banking relationship
                  with the company.)

wird es übel, kommen die aasgeier... LOL & dann wird es noch übler

entgegen panikmachen & in die hosen pipi machen einiger leute hier, hat sich caly bei ca. 0.5$ eingependelt &  rutscht waagrecht ins neue jahr.
sobald die verträge kommen (falls überhaupt) geht es in richtung norden.
der boden ist gesetzt, zementiert & betoniert, denke nicht dass es weiter runter geht, aber who knows...

meine meinung ist, war & bleibt: wer in solche werte investiert ist selber schuld & muss nachher nicht zu mama heulen gehen.
ich bin logo dabei, so ne obertittengeile chance lasse ich mir sicher nicht entgehen.
allen mitaktionären einen mega rutsch & allen stinkern pisse ich mit frisch mit champagner angereicherter pisse ans bein, he he
cya

Der grosse sell off scheint gerade mitten im Gange. Viele wollen offenbar Caly am Jahresende aus dem Depot haben. Schauen wir mal, wie die heute in Ami-Land schliessen werden. Börse F hat ja nun schon zu. Denke, viele werden am Freitag grosse Augen machen.

Mit SL hat das m.E. nix zu tun. Es geht stetig bergab, nur Verkäufe zu verzeichnen. Es könnte die verzögerte Reaktion auf gestrige Meldung sein oder einfach nur das einfahren der diesjährigen Ernte (kommen immerhin von 10 ! US-cent).

eine neue Nachricht ist wie ein neues Leben, aber wie das Leben dann weitergeht, möchte sogar wagen, dass im Amiland heute ein Kurs von 0,65 $ rauskommt, naja träumen darf man doch, irgendwas muß ja jetzt kommen !!!!!!!

Ruhig Blut
gruß werweiß und rutscht gut rüber ins Jahr 2004

euch auch einen guten Rutsch - wird schon wieder mit Caly , ruhig Blut !


auch an alle alten Calyzocker !!!!!! - hat viel Spaß gemacht dieses Jahr mit der Aktie !


Gruß

leo

www.bussinessagainstaids.org nachgesehen, ich muß sagen wenn all die Firmen nur ein bißchen Verstand haben, dann wäre Calypte doch nicht dabei, ist doch eine Betrügerfirma, ne Ihr Pessimisten, da ist was im Gange das haben wir in unseren Träumen noch nicht erlebt, hurra !!!!!!!!!!!!!!!!!!!

Gruß Werweiß

www.businessfightsaids.org jetzt stimmts aber wirklich, möchte eure meinungen mal dazu hören, wow, wow, wow !!!

im neuen Jahr werd ich mich weiter einkaufen. Die spinnen alle!
Grüße Abenteurer

Ich kann mich nicht recht entscheiden. Bin fett im Minus, denke aber langsam mueste doch was passieren bei denen?

gerade 2 mal 4000 Stück geordert, kann nur empfehlen zuzuschlagen!

noch besser, ich sehe heute einen Schlusskurs von mind. 0,65 $ und Montag geht es weiter habe jetzt insgesamt 18000 Stücke in meinem Depot liegen!
Denk daran Dienstag ist Caly Tag

@luckystrike, was machst Du?

es rumpelt und bumpelts balt!
von minus 12 % heute morgen auf jetzt plus 9 % was will mann mehr und das ist erst der Anfang!

das war es vorläufig..

lass der Aktie noch ein wenig Zeit bis die ganzen kleinanleger ihre Mini-Panikverkäufe machen und dann schauen wir weiter, Aktie ist immer noch über 9 % in Amerika im Plus!

aber der tagesdurchschnitt liegt bei fast 4 mio.